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Abstract
Introduction: Treatment-resistant depression (TRD) has a high prevalence and can be exacerbated by poor physical health and
economic hardships, which have become common stressors during the current COVID-19 pandemic. The therapeutic approaches
used to treat these patients are not always available, may be not be accepted by some patients, and often require face-to-face
interactions.
Objective: The main aim of this study will be to evaluate the effectiveness of an Internet-based adjuvant lifestyle-based intervention
for patients with TRD.
Methods: This will be a parallel, randomized, and controlled clinical trial. A total of 180 patients with TRD will be randomly allocated
(1:1:1) to 1 of 3 groups: treatment prescribed by themental health team andwritten suggestions for lifestyle changes (placebo control
group); treatment prescribed by the mental health team, written suggestions for lifestyle changes, and an 8-week mindfulness-based
cognitive therapy program (active control group); or treatment prescribed by the mental health team, written suggestions for lifestyle
changes, and an 8-week lifestyle change promotion program (intervention group). We will perform this study during the COVID-19
pandemic, and will administer interventions by teletherapy, and contact participants by telephone calls, text messages, and/or
teleconferences. We will collect patient data using questionnaires administered at baseline, immediately after the intervention, and
after 6 and 12 months. The primary outcome will be score on the Beck Depression Inventory-II. The secondary outcomes will be
score on the Clinical Global Impressions Scale (used to quantify and track patient progress and treatment response over time) and
health-related quality of life measured using the European Quality of Life-5 Dimensions Questionnaire.
Discussion:Patients with TRD are especially vulnerable when face-to-face psychotherapy is unavailable. The main strength of the
proposed study is the novelty of the intervention to be used as an adjuvant therapy. Our results may provide guidance for treatment of
patients with TRD in future situations that require lockdown measures.
ClinicalTrials registration number: NCT04428099
Abbreviations: AAQ-II = Acceptance and Action Questionnaire-II, BDI-II = Beck Depression Inventory-II, DSM = Diagnostic and
Statistical Manual of Mental Disorders, EQ-5D = European Quality of Life-5 Dimensions Questionnaire, FFMQ = Five Facets of
Mindfulness Questionnaire, GCI = Global Clinical Impression, iCBT = Internet-Based Cognitive Behavioral Therapy, ICD-10 =
International Classification of Diseases, iMBCT = Online Mindfulness-Based Cognitive Therapy, IPAQ-SF = International Physical
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Activity Questionnaire-Short Form, ISI = Insomnia Severity Index, ITCs = information and communications technologies, MBCT =
Mindfulness-Based Cognitive Therapy, MEDAS = Mediterranean Diet Adherence Screener, MINI = Mini-International
Neuropsychiatric Interview, MOS-SS = Medical Outcomes Study Social Support Survey, SCS = Self-Compassion Scale, TRD
= Treatment-Resistant Depression, VAS = Visual Analogue Scale.
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1. Introduction
Major depression is a highly prevalent condition and the second
leading cause of disease-induced disability in Spain,[1,2] even
though there are effective biological, psychosocial, and other
therapeutic treatments. Unfortunately, treatments are not always
available, may not be accepted by patients, and may not provide
satisfactory results.[3,4] Treatment of patients with depression has
become more difficult during the COVID-19 pandemic.
Treatment-resistant depression (TRD) is a controversial con-
struct,[5,6] but a commonly accepted definition is: “an incomplete
or inadequate response to at least 2 pharmacological treatments,
where patients continue to meet DSM-5 criteria for major
depression 1 month after treatment.”[7]
It is therefore necessary to identify therapeutic alternatives for
patients with TRD, such as combinations of standard treatments,
without diminishing tolerance and safety.[8] There is some evidence
that interventions based on improving lifestylemay be effective for
patients with TRD.[9] Lifestyles are changing quickly in developed
countries, and the appearance and persistence of depression are
related to a variety of biological and psychosocial factors that are
related to lifestyle. These include physical inactivity, unhealthy
diet, insomnia, social withdrawal, and excessive stress.[4,8,10]
Therefore, an intervention that promotes lifestyle improvements
may be helpful for patients with TRD.[11–16]
In addition to investigating the effect of modification of
individual lifestyle factors, there has been progress in studying
modification of combinations of lifestyle factors as a therapeutic
tool for various medical conditions and mental disorders, such as
depression.[17–20] We recently tested a multimodal program that
includes interventions that are particularly effective for patients
with depression: daily physical activity, adherence to a
Mediterranean diet, sleep hygiene, and regulated exposure to
sunlight.[21] Other studies also examined the effect of other
interventions, such as promoting sociability and teaching
emotional self-control techniques, that should also be consid-
ered.[22,23] Some researchers proposed this approach as an
alternative to psychotherapy or pharmacotherapy as the first
treatment for depression.[9] There is evidence that the clinical
manifestations of depression decreased at 2 to 6 months after
patients followed specific recommendations regarding improve-
ments to lifestyle.[9] However, this benefit subsequently dis-
appeared, probably because of the limited duration of support,
monitoring, and supervision.[22] Group therapy has the potential
to promote long-term adherence to an intervention program and
improve patient outcome.[24]
Extensive scientific evidence indicates that online treatments
for affective disorders are effective.[25] The benefits of these
treatments, compared with usual treatments, show a clear need to
consider this approach in treatment guidelines for depression,
regardless of symptom severity.[26] Online treatments and
teletherapy could therefore be a cost-effective alternative to
traditional psychological care for the prevention of relapses and
depressive episodes.[27] The “Smile is Fun” program is an
example of an effective online intervention that helped patients
with moderate symptoms of stress and depression.[27]
Previous research of online psychological treatments mainly
focused on Internet-based cognitive behavioral therapy (iCBT),
and found that this was an effective and practical alternative
to face-to-face interventions for treatment of depression.[28]
Some studies also demonstrated the effect of practicing
mindfulness as an online treatment for depression.[27] More-
over, a recent study reported that the combination of practicing
mindfulness and iCBT (iMBCT) had potential for treatment of
depression.[29]
One of the main challenges of Internet-based clinical
interventions is the difficulty in establishing an adequate
therapeutic bond, an essential component for successful
psychological interventions. However, previous studies suggested
that online therapies can establish satisfactory therapeutic
alliances.[30] Despite the great advances in the online treatment
of depression, many aspects of these interventions require further
study, such as the efficacy of online multimodal lifestyle programs
for patients with TRD.
There is little scientific evidence supporting the benefits of an
online adjuvant healthy lifestyle promotion program for patients
with TRD, probably because implementation of these inter-
ventions is difficult.[31] There is evidence that psychotherapy
delivered by telephone or online may be useful for patients with
depression, but less information is available regarding the use of
Internet-based programs that focus on lifestyle in health
emergency situations in which people are required to restrict
their mobility and maintain physical distance.[32,33] As far as we
are aware, no previous studies have examined the effect of this
approach for patients with TRD.
The main objective of this study is to analyze the effectiveness
of treatment prescribed by the mental health team, written
suggestions for lifestyle changes, and an 8-week lifestyle change
promotion program in patients with TRD. There will be 2 control
groups: a placebo control group will receive treatment prescribed
by the mental health team and written suggestions for lifestyle
changes; an active control group will receive treatment prescribed
by the mental health team, written suggestions for lifestyle
changes, and an 8-week iMBCT program, an intervention that
has proven effectiveness in a face-to-face format.[34,35]
We hypothesize that patients randomized to the lifestyle
intervention group will show significantly greater improvements
in clinical measures of depression than patients from the 2 control
groups at 12 months.
2. Methods
2.1. Study registration
The protocol for this study was registered with the ClinicalTrials.
gov registration number: NCT04428099 on June 11, 2020
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(version 1.0). Available online: https://clinicaltrials.gov/ct2/show/
NCT04428099
2.2. Ethics committee
Ethics approval was granted by the Research Ethics Committee of
the Balearic Islands (project approval number IB3925/19PI;
approved May 29, 2019). The study has been developed in
accordance with the Helsinki Declaration. All subjects will sign
an informed consent form before group allocation. Their data
will be anonymized and will only be used for the purposes of the
study. Both participants and healthcare professionals will be
informed of the results. Patients allocated to the control group
will have the opportunity to follow the intervention group
recommendations once the study is finished, if the final results
recommend doing so. The Research Ethics Committee will be
notified of any protocol modifications.
2.3. Research design
This parallel, randomized, controlled trial will be a pragmatic
clinical trial conducted under “real world” conditions. We will
recruit patients from the Balearic Islands (Spain) who have
experienced an episode of TRD. This research protocol has been
prepared according to the SPIRIT statement.[36]
2.4. Participants
2.4.1. Inclusion criteria. The inclusion criteria are age 18 years
or older; male or female; diagnosis of major depressive disorder
based on DSM-5 and Mini-International Neuropsychiatric
Interview (MINI) criteria and at least 2 failed attempts at
psychopharmacological treatment for the episode; ability to
understand written and spoken Spanish; sufficient physical and
cognitive aptitude to understand and provide written informed
consent; and access to technologies and knowledge needed to
engage in online videoconferences at home, with assistance from
family members if necessary.
2.4.2. Exclusion criteria. The exclusion criteria were age less
than 18 years; non-Spanish speaking; presence of another
disease that affects the central nervous system, such as organic
brain pathology, traumatic brain injury of any severity, or
dementia; another psychiatric diagnosis or serious psychiatric
illness, such as (substance dependence or abuse, history of
schizophrenia or other psychotic disorders, eating disorders
(except for anxiety or personality disorders based on medical
history and MINI criteria):[37] presence of a serious or
uncontrolled medical, infectious, or degenerative illness that
may interfere with affective symptoms; presence of delirium or
hallucinations; risk of suicide; pregnancy or breast-feeding;
and the presence of any medical, psychological, or social
problem that could seriously interfere with participation in the
study.
2.5. Intervention
Patients will be randomly allocated to 1 of 3 groups:
1. Intervention group: Treatment prescribed by the mental health
team, written suggestions for lifestyle changes, and an 8-week
lifestyle change promotion program.
2. Placebo-control group: Treatment prescribed by the mental
health team and written suggestions for lifestyle changes.
3. Active-control group: Treatment prescribed by the mental
health team, written suggestions for lifestyle changes, and an
8-week iMBCT program.
The eight 3-hour group sessions administered to the interven-
tion group (Table 1) will include review and assignment of
homework on the following topics about depression and healthy
lifestyles: symptoms, causes, course, and treatment of depression;
importance of physical exercise for physical and mental health;
how to exercise safely and comfortably; motivation to incorpo-
rate physical exercise into daily routines; importance of good
nutrition for improving physical and mental health, and healthy
eating guidelines; importance of a social support network, with
practical proposals for improvements; sleep-wake rhythm and
sleep hygiene, with practical proposals for improvement; need for
appropriate exposure to sunlight, with practical recommenda-
tions; role of negative ruminations in maintaining depression,
with strategies to detect and stop this behavior; contact with
nature, with practical recommendations for improvements. All
strategies will be reviewed and there will be a final opportunity to
recommend their combined long-term use.
The eight 3-hour group sessions administered to the active
control group (Table 1) will review an assignment of homework
on the following topics about depression and mindfulness:
symptoms, causes, course, and treatment of depression; concept
of full attention; changing from living on “automatic pilot” to
living consciously and deliberately; observations of breathing and
the body; changing the form of relating to experiences through
thought to feeling them directly; labeling different experiences
(pleasant, unpleasant); changing from delving into the past and
anticipating the future to being fully present in the moment;
changing from trying to avoid, escape, or eliminate unpleasant
experiences to approaching them with curiosity and interest;
changing from needing things to be different to simply letting
them be as they are; changing from considering thoughts as true
and real to considering them as mental processes that may not
correspond to reality; changing from treating yourself harshly to
caring for yourself with affection and compassion; planning a
future by living mindfully.
2.6. Outcomes measures
The primary outcome measure will be the severity of depression
based on the Beck depression inventory-II (BDI-II). The
secondary outcome measures will be the scores from scales that
rate global clinical impression, quality of life, comorbidities,
social support, mindfulness skills, physical activity, adherence to
the Mediterranean diet, severity of insomnia, self-compassion,
and acceptance and action.
2.6.1. Beck depression inventory-II (BDI-II). The primary
outcome is depression severity, and will be measured using the
BDI-II.[38] This is a self-report that measures the severity of
depression using 21 multiple-choice questions, with each answer
scored from 0 to 3. The Spanish version of the BDI-II was
validated and has a high reliability (Cronbach alpha=0.89).[39]
The standardized cutoffs are: 0 to 13 (minimal depression); 14 to
19 (mild depression); 20 to 28 (moderate depression); and 29 to
63 (severe depression).
2.6.2. Global clinical impression (GCI). The CGI was devel-
oped for use in clinical trials sponsored by the National Institute
of Mental Health as a brief, stand-alone assessment of the
clinician’s view of a patient’s global functioning before and after
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Table 1
Sessions descriptions for the intervention group and the active control group.
Lifestyle change sessions (intervention group) Mindfulness-based cognitive therapy sessions (active control group)
Session Topic Homework Topic Homework
1 Symptoms, causes, course, and
treatment of depression.
Importance of physical exercise for
physical and mental health.
Education on how to exercise
safely and comfortably. Motivation
to incorporate physical exercise
into daily routines.
If physically able, complete an
aerobic exercise plan (at least 30
min, 3 times per week), which will
be increased over time in a
personalized manner.
Symptoms, causes, course, and
treatment of depression. Concept
of full attention. Going from living
on “automatic pilot” to living
consciously and deliberately.
Observe breathing and the body.
Raisin exercise.
Attention to breathing, 24min with audio
every day. Record the facets of life in
which you are not present (brief).
Choose a routine task to perform with
full attention, such as the raisin
exercise. Mindful eating.
2 Importance of good nutrition in
improving physical and mental
health. Education on healthy
eating guidelines, with a focus on
the Mediterranean diet.
Keep a daily food record to
determine the need for dietary
changes.
Change the form of relating to
experiences through thought to
feeling them directly. Label the
experiences (pleasant, unpleasant).
Body scan, 40min with audio every day.
Focusing on breathing, 10min with
audio several times. Complete the
record of pleasant experiences (one
per day, specifying the thoughts,
emotions, and sensations associated
with the experience). Choose a routine
task to perform mindfully this week.
3 Importance of relationships.
Education on how to improve the
social support network, with
practical proposals.
Schedule at least 3 face-to-face or
online meetings with people who
are emotionally close and then
increase the number of these
meetings over time, if possible.
Change from delving into the past
and anticipating the future to
being fully present in the moment.
Conscious stretching (even days). Body
scan (odd days). Record unpleasant
experiences (analogous to pleasant
experiences in Session 2). Breathing
space, 3min 3 times a day at
scheduled times. Appreciation exercise
before bed. Suggestions for daily life.
4 Importance of the sleep-wake
rhythm. Education on how to
improve sleep hygiene, with
practical proposals.
Keep a daily sleep record that
indicates the implementation of
recommendations and the results.
Change from trying to avoid, escape,
or eliminate unpleasant
experiences to approaching them
with curiosity and interest.
Sedentary meditation on unpleasant
experiences, 30min with audio every
day. Record unpleasant experiences
(analogous to pleasant experiences in
session 2). Breathing space, 3min 3
times a day at scheduled times.
Appreciation exercise before bed.
Suggestions for daily life.
5 Importance of regular and safe
exposure to sunlight, with practical
recommendations.
Receive at least 1 h of sunlight per
day and keep a daily record that
includes adherence to the safety
guidelines.
Change from needing things to be
different to simply letting them be
as they are.
Sedentary meditation (sounds and
thoughts) with audio every day.
Breathing space, 3 times a day at
scheduled times and in difficult
moments (coping). Meditative walk
(walking meditation) as a complement
or alternative to seated meditation.
Suggestions for informal practice.
6 Effect of negative ruminations in
maintaining depression. Learning
strategies to detect and stop this
behavior.
Keep a daily record of the estimated
time of depressive ruminations,
strategies used to stop this
behavior, and outcomes.
Change from considering thoughts as
true and real to considering them
as mental processes that may not
correspond to reality.
Sedentary meditation (sounds, thoughts,
emotions, and body), also without
audio support. Breathing space, 3
times a day at scheduled times and in
difficult moments (coping version).
Attention to and recording of repetitive
thoughts. Suggestions for daily life.
7 Importance of contact with nature,
and practical recommendations for
improvements.
Schedule and engage in at least 1
outing to a natural environment
(forest, mountain, beach, or park),
and increase these outings, if
possible.
Change from treating yourself harshly
to caring for yourself with
affection and compassion.
Choose between different practices (body
scan, conscious stretching, walking
meditation, seated meditation,
meditation with difficulties, focusing on
breathing, and mountain meditation) to
create your own program for the
week. Devise an action plan for
difficult moments (cognitive
vulnerability). Breathing space, 3 times
a day at scheduled times and in
difficult moments (coping version).
8 Review of all strategies and a final
opportunity to recommend their
combined long-term use.
Proposals for maintaining all these
strategies in the future.
Plan a future by living mindfully. Proposals for maintaining all these
strategies in the future.
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initiating a study medication.[40] The CGI-Severity (CGI-S) asks
the clinician 1 question: “Considering your total clinical
experience with this particular population, how mentally ill is
the patient at this time?”The answer is rated on a 7-point scale (1,
normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4,
moderately ill; 5, =markedly ill; 6, severely ill; 7, among the most
extremely ill patients). This rating is based on observed and
reported symptoms, behaviors, and function during the past 7
days. The CGI-S score is useful because it can track clinical
progress over time and the score correlates with the scores from
longer and more time-consuming rating instruments used to
assess patients with a diverse psychiatric diagnoses.[41]
2.6.3. Three-level European quality of life-5 dimensions
questionnaire (EQ-5D-3L). The health-related quality of life
will be measured using the EQ-5D-3L,[42,43] and this score will
then be used to calculate the quality-adjusted life-years during the
monitoring period by adjusting the length of time affected by the
health result by the utility value. This scale measures 5 health
dimensions (mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression) each of which is rated at 3 levels (no
problems, slight problems, or moderate/severe problems). The
EQ-5D-3L also records a patient’s self-rated health using a 20-cm
vertical visual analogue scale (VAS), in which the endpoints are
labeled “The best health you can imagine” and “The worst health
you can imagine.” This VAS can be used as a quantitative health
outcome measure that reflects the patient’s own judgment. A
patient marks the point on the vertical line that best reflects his or
her assessment of current global health status.[44] Cronbach’s
alpha coefficient for this scale has been calculated in some
disease-specific populations. We highlight the study by Seoane
et al,[45] in which the overall value was 0.788. One general
population study provided an overall mean estimate of the
Minimum Important Difference for the EQ-5D was 0.074.[46]
2.6.4. International classification of diseases (ICD-10). The
presence of comorbidities and chronic diseases will be recorded
using the ICD-10.[47] We estimate that approximately 50% of
patients will present with at least 1 comorbidity.[48] Anthropo-
metric measures (weight, size, and waist circumference) will also
be recorded.
2.6.5. Medical outcomes study social support survey (MOS-
SS). Social support will be measured using theMOS-SS,[49] a self-
report instrument that has 4 subscales (emotional/informational,
tangible, affectionate, and positive social interaction) and an
overall functional social support index. This scale has good
reliability (Cronbach’s alpha ≥ 0.91) and is stable over time. It
consists of 19 items, each of which is rated using a 5-point Likert
scale. Higher scores indicate greater support. The Spanish
language version of the MOS-SS has been validated.[50]
2.6.6. Five facet mindfulness questionnaire (FFMQ). The
FFMQ[51] is a self-report questionnaire that assesses 5 facets of
mindfulness: observation, description, aware actions, nonjudg-
mental inner experience, and nonreactivity. It contains 39 items,
each of which is rated from 1 (“never or very rarely true”) to 5
(“very often or always true”). The total score is the sum of the
direct and reverse-scored items. The Spanish language version has
been validated and has a Cronbach alpha of 0.88.[52]
2.6.7. Physical activity based on the international physical
activity questionnaire-short form (IPAQ-SF). Physical activity
will be measured using IPAQ-SF.[53] This scale assesses the levels
of habitual physical activity over the previous 7 days. It has 7
items and records activity on 4 intensity levels (vigorous intensity,
moderate intensity, walking, and sitting). A validated Spanish
version is available.[54] This scale has good reliability and
acceptable validity for the measurement of total and vigorous
physical activity, but poor validity for moderate activity.[55]
2.6.8. Mediterranean diet adherence screener (MEDAS).
Adherence to the Mediterranean diet will be measured using the
14-item MEDAS, developed by the PREDIMED study group.[56]
This scale records food consumption habits. It considers the
consumption of olive oil as the main source of cooking fat, white
meat and red meat, servings of vegetables, portions of fruit, red
meat or sausages, animal fat, sugar-sweetened beverages, redwine,
pulses, fish, commercial pastries, and dressing foods with a
traditional sauces consisting of tomatoes, garlic, onions, or leeks
sautéed in olive oil. The total score ranges from 0 to 14, with a
higher score indicating better adherence.[57]
2.6.9. Insomnia severity index (ISI). The ISI[58] will be used to
assess insomnia. This is a self-report instrument that measures a
patient’s perception of nocturnal and diurnal symptoms of
insomnia: difficulties initiating sleep, staying asleep, early
morning awakening, satisfaction with current sleep pattern,
interference with daily functioning, noticeability of impairment
attributed to a sleep problem, and degree of distress or concern
caused by a sleep problem. This scale has 7 items, with each
answer ranging from 0 to 4, and an overall score ranging from 0
to 28. The Spanish version of the ISI[59] has adequate internal
consistency (Cronbach alpha=0.82).
2.6.10. Self-compassion scale (SCS). The original SCS[59] has
26 items that measure 6 components of self-compassion (with
reverse coding of negative aspects): self-kindness, self-judgment,
common humanity, isolation, mindfulness, and over-identifica-
tion.[60] Each item is rated on a 5-point scale that ranges from 1
(“almost never”) to 5 (“almost always”). The Spanish version of
the short form of the SCS (12 items) is a valid and reliable
instrument for evaluation of self-compassion in the general
population.[61]
2.6.11. Acceptance and action questionnaire-II (AAQ-II). The
AAQ-II[62] is a general measure of experiential avoidance and
psychological inflexibility which consists of 7 statements, each of
which is rated from 1 (“never true”) to 7 (“always true”). This
scale measures the unwillingness to experience unwanted
emotions and thoughts and the inability to be in the present
moment and commit to values-directed actions when experienc-
ing psychological events that could undermine them. The Spanish
version of the AAQ-II has good internal consistency, in that
Cronbach’s alpha was 0.88; construct validity, in that the factor
analysis led to a 1-factor solution; discriminant validity, in that
the score discriminated between clinical and nonclinical samples;
and external validity, in that there were strong correlations with a
wide range of psychological symptoms, quality of life, and other
psychological constructs.[63]
2.7. Participant timeline
We will collect patient data using questionnaires administered at
baseline (week-0), immediately after the intervention (week-8), at
month-6, and at month-12 (Table 2).
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2.8. Sample size
Scientific evidence suggests that a 17% reduction in the BDI-II
score[38] is clinically relevant.[64] A previous study by our team
that examined psychiatric outpatients indicated the average BDI-
III score at the beginning of the study was 24.5 (SD=9.8).[9]
Thus, we considered a reduction of 6 points or more to indicate a
clinically significant benefit. We estimate a maximum dropout
rate of 25%. Accepting an a risk of 0.05 and a b risk of 0.15 in a
bilateral contrast, 60 subjects will be required for each group.
Thus, the total sample size will be 180.
2.9. Recruitment
Patients from the Balearic Islands who experienced a TRD
episode will be recruited through cooperation with mental health
workers and applications will be submitted via social media. To
ensure the patients meet the inclusion criteria, the assessors will
administer the MINI questionnaire by telephone, as with all the
other tests.[37] If a participant is eligible, the researcher will
administer the baseline questionnaire. Recruitment and baseline
assessments will be performed until the sample size is 180. All
collected information will be processed as stipulated in current
legislation regarding the protection of personal data.
2.10. Assignment of interventions
Eligible patients will be randomized once they agree to participate
and provide written informed consent. After the enrolment visit,
each patient will be randomly assigned to the MBCT Interven-
tion, Lifestyles Intervention or Placebo group in a 1:1:1 ratio.
Randomization will be performed using a computer-generated
random assignment sequence with a block randomization
method and Random Allocation software (v.2.0). A hospital
unit unrelated to this clinical trial will perform the randomization
of patients to the different study groups.
2.11. Statistical analyses
All researchers conducting the data analysis will be blinded to
group allocations. All eligible randomized patients who were
evaluated at least once using the efficacy indicators will be defined
as the “full analysis set”; all eligible randomized patients who
attend at least 80%of the scheduled sessions will be defined as the
“per-protocol set.” The effectiveness measurements will be
evaluated mainly by intention-to-treat analysis using the full
analysis set and supplemented by per-protocol analysis.
Numerical variables with normal distributions will be presented
as means± standard deviations, and categorical variables as
absolute and relative frequencies. Numerical variables with
skewed distributions will be presented as medians, minima, and
maxima. Analysis of variance will be used to compare the 3 groups
at multiple time points. In the main analysis, missing data will be
replaced using multiple imputation. Complete-case analysis will
be also conducted as a sensitivity analysis to assess the robustness
of results from the multiple imputation procedure. Hypothesis
testing will be performed using a 2-sided test and presented with
95% confidence intervals. A P value less than .05 will indicate
statistical significance. All analyses will be performed using SPSS
version 21.0 and STATA version 16.1.
3. Discussion
Mental health professionals have the responsibility to adapt their
health care interventions to health emergency situations, such as
the current COVID-19 pandemic, and must continue to offer
demonstrably useful therapeutic alternatives to their patients.
Patients with TRD are among the neediest in these circumstances,
because provision of face-to-face care is very difficult. This study
will examine the effect of an intervention that attempts to help
patients with TRD to modify their lifestyles by using information
and communications technologies (ICTs) and videoconferencing
instead of traditional face-to-face interactions. To assess the
efficacy of lifestyle modification, we will compare this interven-
tion group with 2 control groups: a placebo control group, which
will receive minimal assistance (written recommendations for a
healthy lifestyle), and an active control group, which will
participate in an iMBCT program.
The time commitment is the same for the active control
(iMBCT) group and the intervention (lifestyle program) group,
and iMBCT has been used successfully for patients with TRD in
face-to-face settings. We hypothesize that at the end of the 12-
month follow-up, the lifestyle program group will show greater
adherence to the intervention and will therefore experience
greater improvement than the other 2 groups. If this Internet-
based multimodal lifestyle intervention program is useful as an
adjunct to the pharmacological treatment of depression, this
Table 2
Timeline for enrolment, allocation, interventions, and assessments.
Study period
Enrolment Intervention Post-allocation Close-out






MBCT intervention x x
Lifestyles intervention x x
Placebo x
Assessments
Chronic conditions (ICD-10), BDI-II x
BDI-II, GCI, EQ-5D-3L x x X
MOS-SS, IPAQ-SF, MEDAS, ISI x x x
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approach should be considered for the management of patients
with TRD in similar emergency situations.
However, there are certain limitations that we must accept. All
assessment instruments are self-applied to avoid possible assessor
bias. However, it is not possible to blind study subjects in the 3
groups. Therefore, if patients aim to please the research team this
could lead to response bias. To reduce this bias, we will inform all
patients that each complementary treatment may be effective and
will not explain our hypothesis regarding the potential greater
long-term efficacy of the lifestyle intervention program. A second
possible limitation is that certain elderly participants may have
difficulties using ICTs. In these cases, we will recommend the
assistance by family members. Another possible limitation is our
uncertainty of the extent to which the COVID-19 pandemic will
affect our study. In particular, a high infection rate could make it
difficult to recruit participants and could also increase their stress,
due to its adverse effects on health, income, and social factors,
and thus hinder the efficacy of the treatment.
Despite these possible limitations, we believe it is urgent and
necessary to develop an effective new intervention for patients
with TRD who are facing uncertain and difficult situations, such
as the COVID-19 pandemic.
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